Pfizer ($PFE) has completed its acquisition of NextWave Pharmaceuticals. The deal could be worth up to $680 million and gives Pfizer exclusive North American commercialization rights to Quillivant XR (controlled-release methylphenidate hydrochloride), the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. Quillivant XR was developed by NextWave in partnership with Tris Pharma, using Tris Pharma's OralXR+ platform, and was approved in the U.S. in September. It's likely to reach U.S. pharmacies in January 2013. Press release